The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

By sjmartinez • December 2, 2024

Secord AA, Lewin SN, Murphy CG, Cecere SC, Barquín A, Gálvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Pérez MJR, Bonaventura A, Diver EJ, Ayuk SA, Wang Y, Corr BR, Salutari V. The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial. Ann Oncol. 2024 Nov 29:S0923-7534(24)04948-2. doi: 10.1016/j.annonc.2024.11.011. Epub ahead of print. PMID: 39617145.

Tags: antibody-drug conjugate, Folate receptor alpha, heavily pretreated (max 6), Infectious Diseases, Mirvetuximab soravtansine, Platinum-sensitive ovarian cancer, Publications

Association between postdischarge antibiotic use and C. difficile testing as a surrogate for clinically significant diarrhea

Livorsi DJ, Merchant J, Cho H, Goetz MB, Alexander B, Goto M. Association between postdischarge antibiotic use and C. difficile testing as a surrogate for clinically significant[...]

Field evaluation of a dual treponemal/non-treponemal point-of-care test for syphilis within an HIV pre-exposure prophylaxis programme in Hanoi, Vietnam

Biba U, Bui HTM, Nguyen LT, Dang HT, Bui TT, Nguyen TC, Dau NS, Pham LQ, Giang LM, Adamson PC. Field evaluation of a dual[...]

Correction: Empowering Women’s PrEP Choices: Qualitative Insights into Long-Acting PrEP Preferences and Decision-Making during Pregnancy and Breastfeeding in South Africa and Botswana

Chen-Charles J, De Vos L, Vundhla P, Gebengu A, Rousseau E, Bekker LG, Peters R, Mussa A, Morroni C, Toska E, Babalola CM, Klausner JD,[...]